Francesca Barone Sells 13,673 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 13,673 shares of the business’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $8.22, for a total transaction of $112,392.06. Following the completion of the transaction, the insider now directly owns 124,207 shares in the company, valued at $1,020,981.54. This trade represents a 9.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Candel Therapeutics Price Performance

Shares of Candel Therapeutics stock opened at $8.18 on Friday. The firm has a market cap of $265.65 million, a PE ratio of -4.73 and a beta of -1.20. The stock has a 50 day moving average of $6.37 and a 200 day moving average of $6.22. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 1.66. Candel Therapeutics, Inc. has a 12 month low of $1.16 and a 12 month high of $14.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CADL. Barclays PLC grew its stake in shares of Candel Therapeutics by 327.1% in the 3rd quarter. Barclays PLC now owns 28,688 shares of the company’s stock worth $199,000 after buying an additional 21,971 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Candel Therapeutics by 12.8% in the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock valued at $3,112,000 after acquiring an additional 51,111 shares during the last quarter. State Street Corp lifted its holdings in shares of Candel Therapeutics by 4.1% in the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock valued at $3,410,000 after acquiring an additional 19,207 shares during the last quarter. Atom Investors LP purchased a new position in Candel Therapeutics in the third quarter worth about $103,000. Finally, MetLife Investment Management LLC bought a new stake in Candel Therapeutics during the third quarter worth approximately $87,000. 13.93% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $19.00 price target (up previously from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.